CytoSorbents Regains Compliance with Nasdaq Minimum Bid Price Requirement
Why now
Thesis: Delisting risk lifted, but underlying fundamentals unchanged
Catalyst to watch: Next earnings or financing announcements
Main risk: Price could fall back below compliance threshold
Why it matters
Regaining Nasdaq bid-price compliance removes a delisting overhang but signals prior weakness.
Details
PRINCETON, N.J., Sept. 23, 2026 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announces that it has regained compliance with the Nasdaq Stock...
Sources
- prnewswire · 2026-09-23 11:00 UTC